GLMD Earnings Date & History
Galmed Pharmaceuticals Ltd (NASDAQ NMS - GLOBAL MARKET) earnings schedule, consensus estimates and reported results for the last eight quarters.
Last updated Aug 19, 2026 at 5:01 PM ET
Galmed Pharmaceuticals Ltd
Biotechnology
- Next earnings date
- Wednesday, August 26, 2026
- Reporting session
- Time TBD
- EPS estimate
- $-0.40
- Revenue estimate
- —
GLMD earnings history
| Report date | Quarter | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|---|
| Wednesday, July 8, 2026 | Q1 2026 | $-0.39 | $0.29 | +174.8% | $0 |
| Tuesday, March 31, 2026 | Q4 2025 | $-0.52 | $-0.80 | -53.8% | — |
| Wednesday, November 26, 2025 | Q3 2025 | $-0.55 | $-0.33 | +40.1% | $0 |
| Thursday, August 28, 2025 | Q2 2025 | $-0.85 | $-0.63 | +25.6% | $0 |
What the market is watching in GLMD's next report
- The full Earnings Read for this company: focus areas, peer read-through and prior-reaction context.
- Ticker Read combines trend, relative strength and catalysts in one research view.
- Scanners, Impact Radar and the members-only Weekly Watchlist are included.
Get the week's earnings by email
One free email each week: the reports that matter, when they land, and what the market is watching.
Frequently asked questions
- When is the next GLMD earnings date?
- Galmed Pharmaceuticals Ltd is scheduled to report on Wednesday, August 26, 2026 (Time TBD). Dates can change until the company confirms them.
- Does GLMD report before or after the market?
- The next report is scheduled time tbd.
- What EPS is expected for GLMD?
- Consensus EPS for the upcoming quarter is $-0.40.
Calendar data is provided for educational and research purposes only and is not investment advice. Release dates, times, estimates and results can change; always verify against the issuing company or agency.
GLMD earnings discussion
Anyone can read. Any free Hyper Stocks account can join in.
Create a free account to join the discussion. Reading is open to everyone — commenting is free, no subscription needed.
Loading discussion…
Member comments are opinions from individual users, not Hyper Stocks research, and are never personalised investment advice.